Compare SG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SG | ABUS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.3M | 888.5M |
| IPO Year | 2021 | N/A |
| Metric | SG | ABUS |
|---|---|---|
| Price | $5.26 | $4.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $13.54 | $5.00 |
| AVG Volume (30 Days) | ★ 4.1M | 2.0M |
| Earning Date | 02-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $685,184,000.00 | $14,606,000.00 |
| Revenue This Year | $4.08 | $125.30 |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.43 | ★ 116.64 |
| 52 Week Low | $5.14 | $2.71 |
| 52 Week High | $30.12 | $5.10 |
| Indicator | SG | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 31.44 | 47.87 |
| Support Level | $5.83 | $3.62 |
| Resistance Level | $6.59 | $4.26 |
| Average True Range (ATR) | 0.41 | 0.28 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 5.93 | 59.55 |
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.